TY  - JOUR
AU  - Kostić, Vladimir
AU  - Džoljić, Eleonora
AU  - Todorović, Zoran
AU  - Mijajlović, Milija
AU  - Svetel, Marina
AU  - Stefanova, Elka
AU  - Dragašević, Nataša
AU  - Petrović, Igor
AU  - Milošević, Milenko
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1825
AB  - Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted.
AB  - Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine
T1  - Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi
VL  - 69
IS  - 12
SP  - 1067
EP  - 1075
DO  - 10.2298/VSP111114028K
ER  - 

@article{
author = "Kostić, Vladimir and Džoljić, Eleonora and Todorović, Zoran and Mijajlović, Milija and Svetel, Marina and Stefanova, Elka and Dragašević, Nataša and Petrović, Igor and Milošević, Milenko and Kovačević, Ivan and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted., Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine, Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi",
volume = "69",
number = "12",
pages = "1067-1075",
doi = "10.2298/VSP111114028K"
}

Kostić, V., Džoljić, E., Todorović, Z., Mijajlović, M., Svetel, M., Stefanova, E., Dragašević, N., Petrović, I., Milošević, M., Kovačević, I., Miljković, B., Pokrajac, M.,& Prostran, M.. (2012). Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 69(12), 1067-1075.
https://doi.org/10.2298/VSP111114028K

Kostić V, Džoljić E, Todorović Z, Mijajlović M, Svetel M, Stefanova E, Dragašević N, Petrović I, Milošević M, Kovačević I, Miljković B, Pokrajac M, Prostran M. Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled. 2012;69(12):1067-1075.
doi:10.2298/VSP111114028K .

Kostić, Vladimir, Džoljić, Eleonora, Todorović, Zoran, Mijajlović, Milija, Svetel, Marina, Stefanova, Elka, Dragašević, Nataša, Petrović, Igor, Milošević, Milenko, Kovačević, Ivan, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine" in Vojnosanitetski pregled, 69, no. 12 (2012):1067-1075,
https://doi.org/10.2298/VSP111114028K . .

TY  - CONF
AU  - Miljković, Branislava
AU  - Rakić, A.
AU  - Kovačević, Ivan
AU  - Pokrajac, Milena
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/696
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - The role of pharmacist in monitoring pharmacotherapy safety
T1  - Uloga farmaceuta u praćenju bezbednosti farmakoterapije
VL  - 56
IS  - 5
SP  - 812
EP  - 813
UR  - https://hdl.handle.net/21.15107/rcub_farfar_696
ER  - 

@conference{
author = "Miljković, Branislava and Rakić, A. and Kovačević, Ivan and Pokrajac, Milena",
year = "2006",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "The role of pharmacist in monitoring pharmacotherapy safety, Uloga farmaceuta u praćenju bezbednosti farmakoterapije",
volume = "56",
number = "5",
pages = "812-813",
url = "https://hdl.handle.net/21.15107/rcub_farfar_696"
}

Miljković, B., Rakić, A., Kovačević, I.,& Pokrajac, M.. (2006). The role of pharmacist in monitoring pharmacotherapy safety. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(5), 812-813.
https://hdl.handle.net/21.15107/rcub_farfar_696

Miljković B, Rakić A, Kovačević I, Pokrajac M. The role of pharmacist in monitoring pharmacotherapy safety. in Arhiv za farmaciju. 2006;56(5):812-813.
https://hdl.handle.net/21.15107/rcub_farfar_696 .

Miljković, Branislava, Rakić, A., Kovačević, Ivan, Pokrajac, Milena, "The role of pharmacist in monitoring pharmacotherapy safety" in Arhiv za farmaciju, 56, no. 5 (2006):812-813,
https://hdl.handle.net/21.15107/rcub_farfar_696 .

TY  - JOUR
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Brzaković, Branka
AU  - Mehmedagić, Aida
AU  - Brujić, Jelena
AU  - Milanović, Marija
AU  - Pokrajac, Milena
PY  - 2004
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/497
AB  - The aim of this study was to evaluate the influence of smoking on the urine paracetamol elimination. Fourteen healthy female volunteers took part in this controlled study. Seven (23+/-3 years; 50 +/- 2 kg; x+/-SD) were non-smokers and seven (26 +/- 9 years; 58 +/- 8 kg) were smokers (15 cigarettes per day). After administration of 500 mg of paracetamol, urine sampling was performed at specific times (before drug administration and 1, 2, 3, 4, 6, 9, 12, 16 and 24 hours after). The bioanalytical method used for determination of hydrolyzed paracetamol conjugates in urine samples was UV-spectrometry. The obtained pharmacokinetic parameters of paracetamol, first-order elimination rate constant (â) and elimination half-life (t1/2â), were statistically compared between non-smokers and smokers. There were no significant differences in both elimination parameters (â 0.311 1/h; t1/2â 2.23 h non-smokers vs. â 0.346 1/h; t1/2â 2.19 h smokers) between the groups. However, the differences obtained in inter-individual variability in pharmacokinetic parameters (â SD 0.013 , KV 13.4 % ; t1/2â SD 0.227, KV 4.57% nonsmokers vs. â SD 0.108 , KV 90 % ; t1/2â SD 0.684 , KV 14 % smokers) indicate relatively low predictability of paracetamol elimination in smokers. That requires higher attention in dosing this drug in smokers, especially if some other factors also influence.
AB  - U radu je ispitivan uticaj sastojaka duvanskog dima na brzinu eliminacije paracetamola urinom. U kontrolisanom ispitivanju je učestvovalo 14 zdravih dobrovoljaca ženskog pola. Sedam su bili nepušači (23±8 godine; 50±2 kg: X±SD), a sedam (26±9 godina; 58±8 kg; X±SD) pušači (15 cigareta dnevno). Određivan je „ukupan” paracetamol u urinu UV- spektrometrijskom metodom, posle hidrolize konjugata paracetamola i oksidacije dobijenog proizvoda, u prisustvu hipobromita, do obojenog jedinjenja - derivata indofenola. Farmakokinetičkom analizom izmerenih koncentracija u urinu izračunati su farmakokinetički parametri: konstanta brzine eliminacije (â) i poluvreme eliminacije paracetamola (t1/2â). Mada vrednosti ovih parametara kod pušača ukazuju na bržu eliminaciju paracetamola, statističkim poređenjem farmakokinetičkih parametara eliminacije kod pušača (â=0,346 1/h i t1/2â=2,19 h) i nepušača (â=0,311 1/h, t1/2â=2,23 h), nije dobijena značajna razlika ( P lt 0,05). Veće vrednosti SD=0,108 i KV=90 % za â i SD=0,684 i KV= 14, 25 % za t1/2â u grupi pušača, u poređenju sa istim parametrima u grupi nepušača (SD=0,013 i KV=13,4 % za â i SD=0,227 i KV=4,57 % za t1/2â), pokazuju veću inter-individualnu varijabilnost farmakokinetičkih parametara eliminacije paracetamola kod pušača. Posledica je relativno niska predvidivost farmakokinetike paracetamola kod pušača, pa je kod njih potrebna veća pažnja u doziranju leka, naročito ako postoji i uticaj drugih faktora farmakokinetičke varijabilnosti.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - The influence of smoking on the urine paracetamol elimination
T1  - Eliminacija paracetamola urinom kod pušača
VL  - 54
IS  - 5
SP  - 655
EP  - 664
UR  - https://hdl.handle.net/21.15107/rcub_farfar_497
ER  - 

@article{
author = "Kovačević, Ivan and Miljković, Branislava and Brzaković, Branka and Mehmedagić, Aida and Brujić, Jelena and Milanović, Marija and Pokrajac, Milena",
year = "2004",
abstract = "The aim of this study was to evaluate the influence of smoking on the urine paracetamol elimination. Fourteen healthy female volunteers took part in this controlled study. Seven (23+/-3 years; 50 +/- 2 kg; x+/-SD) were non-smokers and seven (26 +/- 9 years; 58 +/- 8 kg) were smokers (15 cigarettes per day). After administration of 500 mg of paracetamol, urine sampling was performed at specific times (before drug administration and 1, 2, 3, 4, 6, 9, 12, 16 and 24 hours after). The bioanalytical method used for determination of hydrolyzed paracetamol conjugates in urine samples was UV-spectrometry. The obtained pharmacokinetic parameters of paracetamol, first-order elimination rate constant (â) and elimination half-life (t1/2â), were statistically compared between non-smokers and smokers. There were no significant differences in both elimination parameters (â 0.311 1/h; t1/2â 2.23 h non-smokers vs. â 0.346 1/h; t1/2â 2.19 h smokers) between the groups. However, the differences obtained in inter-individual variability in pharmacokinetic parameters (â SD 0.013 , KV 13.4 % ; t1/2â SD 0.227, KV 4.57% nonsmokers vs. â SD 0.108 , KV 90 % ; t1/2â SD 0.684 , KV 14 % smokers) indicate relatively low predictability of paracetamol elimination in smokers. That requires higher attention in dosing this drug in smokers, especially if some other factors also influence., U radu je ispitivan uticaj sastojaka duvanskog dima na brzinu eliminacije paracetamola urinom. U kontrolisanom ispitivanju je učestvovalo 14 zdravih dobrovoljaca ženskog pola. Sedam su bili nepušači (23±8 godine; 50±2 kg: X±SD), a sedam (26±9 godina; 58±8 kg; X±SD) pušači (15 cigareta dnevno). Određivan je „ukupan” paracetamol u urinu UV- spektrometrijskom metodom, posle hidrolize konjugata paracetamola i oksidacije dobijenog proizvoda, u prisustvu hipobromita, do obojenog jedinjenja - derivata indofenola. Farmakokinetičkom analizom izmerenih koncentracija u urinu izračunati su farmakokinetički parametri: konstanta brzine eliminacije (â) i poluvreme eliminacije paracetamola (t1/2â). Mada vrednosti ovih parametara kod pušača ukazuju na bržu eliminaciju paracetamola, statističkim poređenjem farmakokinetičkih parametara eliminacije kod pušača (â=0,346 1/h i t1/2â=2,19 h) i nepušača (â=0,311 1/h, t1/2â=2,23 h), nije dobijena značajna razlika ( P lt 0,05). Veće vrednosti SD=0,108 i KV=90 % za â i SD=0,684 i KV= 14, 25 % za t1/2â u grupi pušača, u poređenju sa istim parametrima u grupi nepušača (SD=0,013 i KV=13,4 % za â i SD=0,227 i KV=4,57 % za t1/2â), pokazuju veću inter-individualnu varijabilnost farmakokinetičkih parametara eliminacije paracetamola kod pušača. Posledica je relativno niska predvidivost farmakokinetike paracetamola kod pušača, pa je kod njih potrebna veća pažnja u doziranju leka, naročito ako postoji i uticaj drugih faktora farmakokinetičke varijabilnosti.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "The influence of smoking on the urine paracetamol elimination, Eliminacija paracetamola urinom kod pušača",
volume = "54",
number = "5",
pages = "655-664",
url = "https://hdl.handle.net/21.15107/rcub_farfar_497"
}

Kovačević, I., Miljković, B., Brzaković, B., Mehmedagić, A., Brujić, J., Milanović, M.,& Pokrajac, M.. (2004). The influence of smoking on the urine paracetamol elimination. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 54(5), 655-664.
https://hdl.handle.net/21.15107/rcub_farfar_497

Kovačević I, Miljković B, Brzaković B, Mehmedagić A, Brujić J, Milanović M, Pokrajac M. The influence of smoking on the urine paracetamol elimination. in Arhiv za farmaciju. 2004;54(5):655-664.
https://hdl.handle.net/21.15107/rcub_farfar_497 .

Kovačević, Ivan, Miljković, Branislava, Brzaković, Branka, Mehmedagić, Aida, Brujić, Jelena, Milanović, Marija, Pokrajac, Milena, "The influence of smoking on the urine paracetamol elimination" in Arhiv za farmaciju, 54, no. 5 (2004):655-664,
https://hdl.handle.net/21.15107/rcub_farfar_497 .

TY  - CONF
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Brzaković, Branka
AU  - Brujić, Jelena
AU  - Milanović, Marija
AU  - Pokrajac, Milena
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/396
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Urine paracetamol elimination in healthy smokers
T1  - Eliminacija paracetamola urinom kod pušača
VL  - 52
IS  - 4
SP  - 670
EP  - 671
UR  - https://hdl.handle.net/21.15107/rcub_farfar_396
ER  - 

@conference{
author = "Kovačević, Ivan and Miljković, Branislava and Brzaković, Branka and Brujić, Jelena and Milanović, Marija and Pokrajac, Milena",
year = "2002",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Urine paracetamol elimination in healthy smokers, Eliminacija paracetamola urinom kod pušača",
volume = "52",
number = "4",
pages = "670-671",
url = "https://hdl.handle.net/21.15107/rcub_farfar_396"
}

Kovačević, I., Miljković, B., Brzaković, B., Brujić, J., Milanović, M.,& Pokrajac, M.. (2002). Urine paracetamol elimination in healthy smokers. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 52(4), 670-671.
https://hdl.handle.net/21.15107/rcub_farfar_396

Kovačević I, Miljković B, Brzaković B, Brujić J, Milanović M, Pokrajac M. Urine paracetamol elimination in healthy smokers. in Arhiv za farmaciju. 2002;52(4):670-671.
https://hdl.handle.net/21.15107/rcub_farfar_396 .

Kovačević, Ivan, Miljković, Branislava, Brzaković, Branka, Brujić, Jelena, Milanović, Marija, Pokrajac, Milena, "Urine paracetamol elimination in healthy smokers" in Arhiv za farmaciju, 52, no. 4 (2002):670-671,
https://hdl.handle.net/21.15107/rcub_farfar_396 .